Next-generation therapeutic angiogenesis by a pharmaceutical pretreatment for the ischemic tissue before an intramuscular injection of endothelial progenitor cells

Research Project

Project/Area Number	24591080
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Circulatory organs internal medicine
Research Institution	Kurume University
Principal Investigator	SASAKI KEN-ICHIRO 久留米大学, 循環器病研究所, 講師 (70320190)
Project Period (FY)	2012-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000) Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	血管新生療法 / 虚血下肢組織 / 酸化ストレス / 血管内皮前駆細胞 / アポトーシス / 虚血組織 / 骨格筋細胞 / ミトコンドリア / 血管新生 / プロピオン酸塩 / 虚血下肢 / 組織ダメージ / アシルカルニチン / 虚血肢組織ダメージ評価
Outline of Final Research Achievements	Ischemic limb tissue was highly exposed to oxidative stress and a lot of endothelial progenitor cells injected to the tissue were led to apoptosis before playing the role for augmenting neovascularization in mice. The tissue condition impaired the mitochondria function, the neovascularization-related inflammatory cytokine secretory function, and the glucose transport function of the skeletal muscle cell. A pretreatment with the nebulization of propionate, which is a pharmacologic chemical agent with a potential for curing low oxygen-induced mitochondria dysfunction, for the mouse ischemic limb tissue augmented the recovery of blood flow in the limb that was subsequently injected endothelial progenitor cells. This result might be due to a recovery of the impaired functions of the skeletal muscle cell, suggesting a hint for the development of next-generation therapeutic angiogenesis.